TrialClinical cancer research : an official journal of the American Association for Cancer Research2020

Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer.

G Travis Clifton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.